Under the agreement, Covidien will purchase certain manufacturing assets of BridgePoint and will also gain rights to license its peripheral vascular products including BigBoss Catheter, Mantaray Catheters and the Mantaray Guidewire.

BridgePoint’s remaining assests comprising of the coronary Chronic Total Occlusion (CTO) products, intellectual property, its employees, and all other non-vascular applications will remain with the company.